GH Research PLC GHRS 深 沪
已收盘 12-19 16:00:00 美东时间
12.96
+0.240
+1.89%
华盛通- 最 高13.33
- 今 开12.84
- 成交量 77.66万股
- 最 低 12.6288
- 昨 收 12.72
- 总市值 8.04亿
- 52周最高 20.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.95
- 委 比 99.60%
- 总股本 6202.94万
- 历史最高 30.43
- 量 比 2.87
- 振 幅 5.51%
- 历史最低 5.05
- 每 手 1
- 风险率 2.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GH Research to Present Promising Results on GH001 at ACNP 2026
GH Research ( ($GHRS) ) has provided an update. GH Research PLC announced its a...
11-24 23:48
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
GH Research Q3 EPS $(0.23) Beats $(0.24) Estimate
GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 2.95 percent. This is unchanged from the same period last year.
11-06 20:19
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
GH Research PLC reported Q3 2025 financial results with $293.9M in cash, up from $182.6M in 2024. R&D expenses rose 26% to $10.6M, while G&A expenses climbed 43% to $6.0M. Net loss was $14.0M, stable vs. prior year. The company updated on GH001, meeting primary endpoint in TRD with -15.5 MADRS reduction (p<0.0001), and showed 73% remission rate at 6 months with good safety. Engagement with FDA continues to address IND hold. Global pivotal trial...
11-06 12:00
GH Research’s GH001 Trial Results to be Presented at ACNP Meeting
The latest announcement is out from GH Research ( ($GHRS) ). GH Research PLC an...
10-17 19:29
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Depression-Focused GH Research Shares Could See Significant Upside: Analyst
GH Research's GH001 shows strong Phase 2 results for treatment-resistant depression, with FDA issues nearly resolved and $1.9 billion U.S. potential.
10-14 02:07
GH Research to Present Long-Term Data on Depression Treatment at 38th European Neuropsychopharmacology Congress
GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a
10-09 19:14
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
GH Research PLC, a clinical-stage biopharmaceutical company, announced the acceptance of a presentation and posters at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam. The presentation will highlight long-term safety and efficacy data from a Phase 2b open-label extension (OLE) study of GH001 in treatment-resistant depression (TRD). Positive safety findings and rapid-acting potential of GH001 reinforce its ...
10-09 11:00
Shares of psychedelic companies are trading higher after a GOP senator stated he's "confident" that under the Trump administration, lawmakers will help secure alternative treatment options for military veterans, including access to psychedelic medicine.
Shares of psychedelic companies are trading higher after a GOP senator stated h...
08-26 02:53
